@article{oai:kanazawa-u.repo.nii.ac.jp:00047523,
 author = {棟居, 聖一 and 原島, 愛 and 武内　, 章彦 and 土屋, 弘行 and 山本, 靖彦 and El‑Far, Ali Hafez Ali MohammedTsuchiya Hiroshi Yamamoto Hazem M.E. Shaheen Yasser S. El‑Sayed Shuhei Kawano Sei‑Ichi Tanuma Yasuhiko Yamamoto and Munesue, Seiichi and Harashima, Ai and Satoh, Akira and Shindo, Mika and Nakajima, Shingo and Inada, Mana and Tanaka, Mariko and Takeuchi, Akihiko and Tsuchiya, Hiroyuki and Yamamoto, Hiroshi and Shaheen, Hazem M.E. and El‑Sayed, Yasser S. and Kawano, Shuhei and Tanuma, Sei‑Ichi and Yamamoto, Yasuhiko},
 issue = {4},
 journal = {Oncology Letters},
 month = {Apr},
 note = {Receptor for advanced glycation end-products (RAGE) is a pattern recognition receptor implicated in the pathogenesis of certain types of cancer. In the present study, papaverine was identified as a RAGE inhibitor using the conversion to small molecules through optimized‑peptide strategy drug design system. Papaverine significantly inhibited RAGE‑dependent nuclear factor κ‑B activation driven by high mobility group box‑1, a RAGE ligand. Using RAGE‑ or dominant‑negative RAGE‑expressing HT1080 human fibrosarcoma cells, the present study revealed that papaverine suppressed RAGE‑dependent cell proliferation and migration dose‑dependently. Furthermore, papaverine significantly inhibited cell invasion. The results of the present study suggested that papaverine could inhibit RAGE, and provided novel insights into the field of RAGE biology, particularly anticancer therapies., Embargo Period 6 months, 金沢大学医薬保健研究域医学系},
 pages = {4627--4634},
 title = {In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.},
 volume = {15},
 year = {2018}
}